Eganelisib (IPI-549) Liposomes, Formulation WNX5.2

Mfr.No.	DLL-0015, DLL-0015-A1-10ML
Alternative Names	IPI-549
Average Size	70-120 nm
Hydration Solution	292 mM sucrose, 0.5% DPBS (1X)
External Solution	WNX5.2
Signaling pathway	PI3K
Description	PEGylated liposomes containing PI3Kgamma inhibitor Eganelisib (IPI-549). Eganelisib (IPI-549) is a potent and selective PI3Kgamma inhibitor (IC50 16 nM) which is reported to exhibit more than 100-fold selectivity over other lipid and protein kinases and potentiate immunotherapy with immune checkpoint inhibitors in mice. IPI-549 is insoluble in aqueous media. This product is a pre-formulated liposomal version of IPI-549 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
Concentration	2.0 mg/mL
Concentration Total Lipid	60 mM
Cas Number	1693758-51-8
Types of Liposomes	Drug Loaded Liposomes
Target	PI3Kgamma

Have you used this product?

Combination SKU	Supplier No.	Volume	Your price	Quantity
BHB19400009-1	DLL-0015-A1-10ML	10mL	$2995		Add to Cart